Table 1 Patient demographic data, past history and individual renal and oncological outcomes
Kidney Biopsy | Age range (yr) | Gender | BMI (kg/m2) | Comorbidities | Medications prior to renal IrAE | Immunotherapy regimen | Renal function 3m | Oncological outcome |
|---|---|---|---|---|---|---|---|---|
Yes | 40-49 | Male | 25.1 | Nil | Nil | Ipilimumab + Nivolimumab | CKD 2 | CR |
Yes | 50-59 | Male | 25.6 | HTN | Metoprolol 50mg twice daily, amdodipine 10mg daily | Ipilimumab + Nivolimumab | CKD 3a | CR |
Yes | 60-69 | Male | 26.2 | Nil | Nil | Ipilimumab + Nivolimumab | CKD 2 | PR |
Yes | 70-79 | Male | 29.2 | HTN, BPH, nephrolithiasis, acquired hypopituitarism | Thyroxine 100mcg daily, Prednisolone 10mg daily. | Ipilimumab + Nivolimumab | CKD 3a | PR |
Yes | 70-79 | Male | 27.5 | HTN, dyslipidaemia, IHD, BPH, GORD | Quinapril 5mg daily, rosuvastatin 20mg daily, allopurinol 200mg daily, rabeprazole 20mg daily. | Pembrolizumab + Epacadostat | CKD 3a | PD |
Yes | 70-79 | Male | 24.6 | HTN, IHD, DM, Diverticular disease. | Amitriptyline 50mg daily, telmisartan 40mg daily. | Ipilimumab + Nivolimumab | CKD 3a | PD |
Yes | 70-79 | Male | 29.2 | IHD, BPH, HTN | Aspirin 100mg daily, clopidogrel 75mg daily, atorvastatin 20mg daily. | Ipilimumab + Nivolimumab | CKD 3b | PD |
Yes | 60-69 | Female | 41.2 | HTN, GORD, rectal cancer. | Perindopril 2.5mg daily, rabeprazole 20mg daily. | Ipilimumab + Nivolimumab | CKD 3a | CR |
Yes | 70-79 | Male | 28.5 | Acquired hypopituitarism | Hydrocortisone twice daily, thyroxine 100mg daily | Ipilimumab + Nivolimumab | CKD 4 | CR |
Yes | 50-59 | Male | 26 | Previous pulmonary embolus | Nil | Ipilimumab + Nivolimumab | CKD 5 | CR |
Yes | 80-89 | Male | 23 | Idiopathic cardiomyopathy. PMR. | Data not available | Pendrolizumab | CKD 3b | SD |
Yes | 30-39 | Male | 27 | Nil | Nil | Ipilimumab + Nivolimumab | CKD 2 | PD |
No | 40-49 | Male | 35.9 | HTN, Obesity, Depression | Perindopril 5mg daily, venlafaxine 75mg daily | Ipilimumab + Nivolimumab | CKD 2 | CR |
No | 70-79 | Male | 28.1 | T2DM, HTN, IHD, dyslipidaemia, smoker, BPH | Quinapril 5mg daily, rosuvastatin 20mg daily, metformin 1000mg daily, gliclazide 60mg daily, dapaglifozin (unknown dose) daily. | Ipilimumab + Nivolimumab | CKD 3a | PD |
No | 70-79 | Female | 31.6 | HTN, dyslipidaemia | Data not available | Ipilimumab + Nivolimumab | CKD 3a | PD |
No | 70-79 | Male | 33 | T2DM, HTN, dyslipidaemia, IHD, PVD, BPH, haemochromatosis, EtOH excess | Aspirin 100mg daily, clopidogrel 75mg daily, perindopril 5mg daily, hydrochlorothiazide 12.5mg daily, amlodipine 10mg, atorvastatin 40mg daily. | Ipilimumab + Nivolimumab | CKD 3b | CR |
No | 50-59 | Male | 31.3 | Nil | Data not available | Pendrolizumab | Full recovery | PR |
No | 60-69 | Male | 27.8 | HTN, CVA, cardiomyopathy. | Bisoprolol 5mg daily | Ipilimumab + Nivolimumab | CKD 3a | PR |
No | 70-79 | Male | 24.9 | HTN, Seizures, | Aspirin 100mg daily, irbesartan 150mg daily, alendronate, simvastatin 40mg daily, Omeprazole 20mg daily, monoxidine 200mcg daily. | Ipilimumab + Nivolimumab | CKD 3b | CR |
No | 60-69 | Male | N/A | Nil | Nil | Ipilimumab + Nivolimumab | CKD 2 | PR |
No | 70-79 | Male | N/A | IHD, T2DM, dysllipidaemia. | Candesartan 32mg daily, aspirin 100mg daily, clopidogrel 75mg daily, simvastatin 40mg daily, propanolol 80mg daily, Ranitidine 150mg daily | Ipilimumab + Nivolimumab | CKD3b | CR |
No | 70-79 | Male | 27.5 | Bladder Ca (sx), IHD, AF, DVT | Aspirin 100mg daily, nicorandil 10mg daily, rosuvastatin 20mg. | Pembrolizumab | CKD 3a | CR |
No | 80-89 | Male | N/A | Bullous pemphigoid, DM, DVT, PVD, AF | Apixaban 2.5mg twice daily, metformin 1000mg daily, rosuvastatin 20mg daily, pantoprazole 40mg daily, gliclazide 60mg daily. | Nivolimumab | CKD 3b | PD |